Section Arrow
EYPT.NASDAQ
- EyePoint Inc.
Quotes are at least 15-min delayed:2026/02/19 13:47 EST
Regular Hours
Last
 14.465
+0.105 (+0.73%)
Day High 
15.14 
Prev. Close
14.36 
1-M High
16.73 
Volume 
1.26M 
Bid
14.45
Ask
14.48
Day Low
14 
Open
14.32 
1-M Low
12.11 
Market Cap 
1.19B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.42 
20-SMA 14.1 
50-SMA 15.85 
52-W High 19.11 
52-W Low 3.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.00/-3.57
Enterprise Value
1.21B
Balance Sheet
Book Value Per Share
2.42
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
43.27M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.2068+0.0148+7.71%0.09PE
IBRXImmunityBio8.42-0.12-1.41%-- 
DRMADermata Therapeutics Inc2.055+0.775+60.55%0.08PE
GERNGeron Corp1.875-0.065-3.35%-- 
ENVBEnveric Biosciences Inc.2.3201+0.0801+3.58%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.